Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
14.74
+0.10 (0.68%)
At close: Apr 2, 2026, 4:00 PM EDT
14.85
+0.11 (0.75%)
After-hours: Apr 2, 2026, 7:38 PM EDT
Amarin Corporation Revenue
In the year 2025, Amarin Corporation had annual revenue of $213.65M, down -6.55%. Amarin Corporation had revenue of $49.22M in the quarter ending December 31, 2025, a decrease of -21.00%.
Revenue (ttm)
$213.65M
Revenue Growth
-6.55%
P/S Ratio
1.44
Revenue / Employee
$2,670,575
Employees
80
Market Cap
306.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 213.65M | -14.97M | -6.55% |
| Dec 31, 2024 | 228.61M | -78.30M | -25.51% |
| Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
| Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
| Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
| Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
| Dec 31, 2019 | 429.76M | 200.54M | 87.49% |
| Dec 31, 2018 | 229.21M | 48.11M | 26.56% |
| Dec 31, 2017 | 181.10M | 51.02M | 39.22% |
| Dec 31, 2016 | 130.08M | 48.33M | 59.11% |
| Dec 31, 2015 | 81.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
| Biogen | 9.89B |
| Grifols | 8.83B |
| Organon & Co. | 6.22B |
| Scilex Holding Company | 40.36M |
AMRN News
- 5 weeks ago - Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease - GlobeNewsWire
- 2 months ago - US Supreme Court to hear 'skinny label' patent fight involving Amarin - Reuters
- 3 months ago - Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization - GlobeNewsWire
- 5 months ago - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - GlobeNewsWire
- 5 months ago - Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 5 months ago - Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress - GlobeNewsWire